Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Complement 3 level in the cerebrospinal fluid in multiple sclerosis]

A Wajgt

    Neurologia I Neurochirurgia Polska
    |May 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

    Neurology·2007
    Same author

    MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

    Neurology·2007
    Same author

    Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

    Neurology·2007
    Same author

    Infusion-related hypersensitivity reactions during natalizumab treatment.

    Neurology·2006
    Same author

    Blood levels of selected hormones in patients with multiple sclerosis.

    Medical science monitor : international medical journal of experimental and clinical research·2001
    Same author

    [Spontaneous intracranial epidural accumulation of air in a patient with excessive skull pneumatization].

    Neurologia i neurochirurgia polska·2001

    Levels of the C3 complement component were significantly lower in the cerebrospinal fluid of multiple sclerosis patients, correlating with serum levels. This suggests no evidence of local complement consumption within the central nervous system in multiple sclerosis.

    Area of Science:

    • Neuroimmunology
    • Biochemistry

    Context:

    • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS).
    • The complement system, particularly the C3 component, plays a role in immune responses and inflammation.
    • Understanding complement levels in MS cerebrospinal fluid (CSF) and serum is crucial for elucidating disease mechanisms.

    Purpose:

    • To determine the absolute and relative levels of the C3 complement component in the CSF and serum of multiple sclerosis patients.
    • To compare C3 levels in MS patients with control groups (neurosis, organic CNS diseases).
    • To investigate potential local consumption of complement within the CNS in MS.

    Summary:

    • Radial diffusion assays revealed significantly lower absolute and relative C3 levels in the CSF of 61 MS patients compared to controls (p < 0.001).

    Related Experiment Videos

  • CSF C3 levels in MS were independent of total protein and albumin concentrations and strongly correlated with serum C3 levels (r = 0.816).
  • No statistically significant difference in the C3 index was observed between MS subgroups with low versus normal CSF C3, indicating no evidence of local complement consumption in the CNS.

    • Impact:

    • Findings suggest that reduced CSF C3 in MS is primarily due to lower serum levels, not local CNS consumption.
    • This research contributes to understanding the systemic and central nervous system complement dynamics in multiple sclerosis.
    • Further investigation into temporarily reduced complement consumption in demyelination areas may be warranted.